Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319657 · ClinicalTrials.gov registry record · Phase 1
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
A Phase 1 study of Immune Tolerance, sponsored by Stanford University.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00319657: Active Phase 1 study of Immune Tolerance, sponsored by Stanford University.
NCT00319657 is a Phase 1 study of Immune Tolerance that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00319657, a Phase 1 study of Immune Tolerance, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone Marrow Transplantation are enrolling patients into a research study to determine if blood stem cells injected after kidney transplantation, in combination with lymphoid irradiation ,will change the immune system such that immunosuppressive drugs can be completely withdrawn. Patients must have a healthy, completely human leukocyte antigen (HLA)-matched brother or sister as the organ and stem cell donor. One to two months before kidney transplant surgery, blood stem cells will be removed from the donor and the cells will be frozen. After transplant surgery, the recipient will receive radiation and anti-T cell antibody treatments for two weeks to prepare for injection of the stem cells. The stem cells will be injected at the end of the two-week treatment. If the stem cells persist in the recipient, immunosuppressive drugs will be gradually reduced until they are withdrawn completely at least six months after transplantation. Patients will be followed in the Stanford clinics for transplant patients. Patients who live outside of the San Francisco Bay Area must remain near Stanford for six weeks after transplant surgery.
Conditions Studied
Interventions
- BIOLOGICAL Hematopoietic cell transplantation
- RADIATION Total lymphoid irradiation
Study Locations (1)
California
- Stanford University, School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2004-07 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319657
The ClinicalTrials.gov registry entry for NCT00319657 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Tolerance appearing as the primary indexed condition, and to 2 interventions - of which Hematopoietic cell transplantation is the first listed.
NCT00319657 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00319657 about?
NCT00319657 is a clinical study titled "Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs". The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone Marrow Transplantation are enrolling patients into a research study to determine if blood stem cells injected after kidney transplantation, in combination with lymphoid irradiation ,will change the immune sys...
What is the current status of trial NCT00319657?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2004-07. Estimated completion is 2026-07.
What conditions does trial NCT00319657 study?
This clinical trial studies the following conditions: Immune Tolerance.
What interventions are being tested in trial NCT00319657?
The interventions under investigation include: Hematopoietic cell transplantation (BIOLOGICAL), Total lymphoid irradiation (RADIATION).
Who is sponsoring clinical trial NCT00319657?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00319657 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Tolerance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.